Akorn Appeals Fresenius Kabi Ruling
18 Oktober 2018 - 07:47PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that the company filed a
notice of appeal to the Supreme Court of the State of Delaware from
the recent decision of the Delaware Court of Chancery rejecting
Akorn’s claims. Akorn has also filed a motion seeking
expedited proceedings in its appeal.
Akorn disagrees with the opinion issued October 1 by the Court
of Chancery.
Despite misleading allegations made by Fresenius throughout the
trial regarding Akorn’s regulatory compliance practices and
activities, Akorn takes data integrity and other U.S. Food and Drug
Administration (“FDA”) compliance issues very seriously.
Akorn is focused on working collaboratively with the FDA as Akorn
continues to evaluate and improve its practices and procedures to
ensure compliance with FDA regulations.
On October 10, Akorn announced it received a new Abbreviated New
Drug Application (ANDA) approval from the FDA for Bimatoprost
Ophthalmic Solution, 0.03%, which is indicated to treat
hypotrichosis of the eyelashes by increasing their growth including
length, thickness and darkness.
Details of Akorn’s appellate argument will be available in
Akorn’s opening brief, which will be filed on a schedule set by the
Supreme Court.
About Akorn
Akorn, Inc. is a specialty generic pharmaceutical company
engaged in the development, manufacture and marketing of
multisource and branded pharmaceuticals. Akorn has manufacturing
facilities located in Decatur, Illinois; Somerset, New Jersey;
Amityville, New York; Hettlingen, Switzerland and Paonta Sahib,
India that manufacture ophthalmic, injectable and specialty sterile
and non-sterile pharmaceuticals. Additional information is
available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
Von Mär 2023 bis Mär 2024
Echtzeit-Nachrichten über Akorn Inc (NASDAQ): 0 Nachrichtenartikel
Weitere News-Artikel